---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-255157"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:58:07.940089+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences Q3 net loss $61.8M; first RNA editing in humans for AATD achieved

## Summary
- Net loss $61.8M vs net income $7.3M in Q3 2023; revenue ($7.7M) vs $49.2M (including one-time events).
- Cash $310.9M at Sep 30, 2024; plus ~$28M net proceeds from greenshoe; runway into 2027.
- First-ever RNA editing in humans: WVE-006 in RestorAATion-2 showed mean M-AAT 6.9 µM at day 15 (60%+ of total AAT).
- WVE-007 (INHBE GalNAc-siRNA) obesity clinical trial on track for 1Q 2025; preclinical data supports monotherapy and GLP-1 synergy.
- WVE-003 HD: FDA open to caudate atrophy endpoint for accelerated approval; IND submission expected 2H 2025.

## SEC filing metadata
- accession: 0001193125-24-255157
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312524255157/0001193125-24-255157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312524255157/d853532d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-255157
- JSON: https://secwatch.observer/filing/0001193125-24-255157.json
- Plain text: https://secwatch.observer/filing/0001193125-24-255157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.